Diverse product portfolio with solid positions in pharmaceuticals and nutritionals; Core drugs--Plavix, Avapro, Abilify, Reyataz, and Erbitux--with relatively long patent lives remaining; Productive R&D pipeline, with a number of promising near-term prospects; and Long-standing modest financial risk profile, with ample liquidity. Loss of patent protection for Plavix and Avapro, which collectively account for 31% of sales, one after the other within a brief period (2011-2012). The ratings on New York, N.Y.-based Bristol-Myers Squibb Co. reflect the company's diverse product portfolio, the addition of several promising new products over the past several years, and solid financials. Bristol-Myers' portfolio remains diverse, with strong positions in the oncology, cardiovascular, and virology markets. Still, the upholding of the patent on Plavix, an anti-platelet aggregator,
